Shanthi Ganesh, Min Ju Kim, Jenny Lee, Xudong Feng, Krisjanis Ule, Amy Mahan, Harini Sivagurunatha Krishnan, Zhe Wang, Maryam Yahyaee Anzahaee, Garima Singhal, Ilia Korboukh, Jennifer A Lockridge, Laura Sanftner, Rene Rijnbrand, Marc Abrams, Bob D Brown
Malignant tumors are often associated with an immunosuppressive tumor microenvironment (TME), rendering most of them resistant to standard-of-care immune checkpoint inhibitors (CPIs). Signal transducer and activator of transcription 3 (STAT3), a ubiquitously expressed transcription factor, has well-defined immunosuppressive functions in several leukocyte populations within the TME. Since the STAT3 protein has been challenging to target using conventional pharmaceutical modalities, we investigated the feasibility of applying systemically delivered RNA interference (RNAi) agents to silence its mRNA directly in tumor-associated immune cells...
March 27, 2024: Molecular Therapy